Differential diagnosis of type 2 neurofibromatosis: Molecular discrimination of NF2 and sporadic vestibular schwannomas

Journal of Medical Genetics

Volumn 35, Issue 12, 1998, Pages 973-977

  Wu, C L ^a   Thakker, N ^a   Neary, W ^a,b   Black, G ^c   Lye, R ^b   Ramsden, R T ^b   Read, A P ^a   Evans, D G R ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

Author keywords

Mutation; Neurofibromatosis type 2; Somatic mosaicism; Vestibular schwannoma

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROGENIC TUMOR; PRIORITY JOURNAL; PROGENY; SEX CHROMOSOME MOSAICISM; TUMOR; VESTIBULAR DISORDER;

EID: 0031788461     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.35.12.973     Document Type: Article

References (29)

1. Kanter WR, Eldridgc R, Fabricant R, Allen JC, Koerber T. Central neurofibromatosis with bilateral acoustic neuroma. Genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 1980;301:851-9.
2. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
3. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-1.
4. Evans DGR, Ramsden R, Huson SM, et al. Type 2 neurofibromatosis: the need for supraregional care. J Laryngol Otol 1993;107:401-6.
5. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820.
6. Evans DGR, Trueman L, Wallace A, Wu CL, Strachan T. Mosaicism in classical NF2: a common mechanism for sporadic disease in tumour prone syndromes? Am J Hum Genet (in press).
7. Wertelecki W, Rouleau GA, Superneau DW, et al Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. N Engl J Med 1988;319:78-83.
8. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363: 515-21.
9. Troffater JA, MacCollin M, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993:72:791-800.
10. MacColIin M, Ramesh V, Jacoby LB, et al. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 1994;55:314-20.
11. Bourn D, Carter SA, Mason S, Evans DGR, Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet 1994;5:813-16.
12. Merel P, Hoang-Xuan K, Sansom M, et al. Screening for germune mutations in the NF2 gene. Genes Chrom Cancer 1995;12:117-27.
13. Parry DM, MacCollin M, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-39.
14. Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42.
15. Neary W, Newton VE, Laiode-Kemp SN, et al. A clinical, genetic and audiological study of patients with type 2 neurofibromatosis. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. J Laryngol Otol 1993:107:634-40.
16. Wu CL, Sloan P, Read AP, Harris R, Thakker NS. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 1994;54:6484-8.
17. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766-70.
18. Jacoby LB, MacCollin M, Louis DN, et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-19.
19. Lenke U, Hanke R, Kraft U, Grade I, Grunewald I, Speer A. Non-isotopic analysis of single strand conformation polymorphism (SSCP) in the exon 13 region of the human dystrophin gene. J Med Genet 1993;30:951-4.
20. Bourn D, Strachan T. Highly polymorphic dinucleotide repeat at the NF2 locus. Hum Genet 1995;95:712.
21. Gyapay G, Morisette J, Vignal A, et al. The 1993-4 Généthon human genetic linkage map. Nat Genet 1994;7: 246-339.
22. Trapman J, Sleddens HFBM, van der Weiden MM, et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicated a candidate tumour suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994;54:6061-4.
23. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis. II. Guidelines for genetic counselling. J Med Genet 1992;29:847-52.
24. National Institutes of Health Consensus Development Conference Statement on Neurofibromatosis. Neurofibromatosis Res Newl 1987;3:3-6.
25. Tos M, Thomsen J. Epidemiology of acoustic neuromas. J Laryngol Otol 1984;98:685-92.
26. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the north west of England and the UK. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
27. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER. Somatic gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 1994;3:347-50.
28. Draper GJ, Sanders BM, Brownbill PA, Hawkins MM. Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. Br J Cancer 1992;66:211-19.
29. Martuza RL, Ojemann RG. Bilateral acoustic neuromas: clinical aspects, pathogenesis and treatment. Neurosurgery 1982;10:1-12.